Description: Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York.
Home Page: www.pfizer.com
PFE Technical Analysis
235 East 42nd Street
New York,
NY
10017
United States
Phone:
212 733 2323
Officers
Name | Title |
---|---|
Dr. Albert Bourla D.V.M., DVM, Ph.D. | Chairman & CEO |
Mr. Frank A. D'Amelio | CFO & Exec. VP |
Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical |
Mr. Douglas M. Lankler | Exec. VP & Gen. Counsel |
Mr. John D. Young | Advisor |
Ms. Angela Hwang | Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. |
Mr. David M. Denton | Chief Financial Officer & Exec. VP |
Ms. Jennifer B. Damico | Sr. VP, Controller & Principal Accounting Officer |
Ms. Lidia L. Fonseca | Exec. VP and Chief Digital & Technology Officer |
Mr. Christopher J. Stevo CFA | Sr. VP & Chief Investor Relations Officer |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 10.9649 |
---|---|
Trailing PE: | 9.0057 |
Price-to-Book MRQ: | 3.3014 |
Price-to-Sales TTM: | 3.013 |
IPO Date: | 2012-08-13 |
Fiscal Year End: | December |
Full Time Employees: | 79000 |